Buy Rating for COMPASS Pathways Driven by Positive Phase 3 Trial Results and Strong Clinical Execution

H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on CMPS stock, giving a Buy rating on June 30.

Patrick Trucchio has given his Buy rating due to a combination of factors including the positive outcomes from the Phase 3 COMP005 trial, which marked a regulatory milestone for COMP360 in treatment-resistant depression (TRD). The trial demonstrated significant improvement in depression symptoms, as measured by the MADRS scale, following a single dose of COMP360. This success is further bolstered by the ongoing COMP006 trial, which aims to explore the durability and re-dosing strategy of COMP360, with results expected in the second half of 2026.
Trucchio’s confidence in COMPASS Pathways is reinforced by the company’s strong clinical execution, safety profile, and regulatory strategy. The COMP005 trial’s use of a true placebo and rigorous trial design has set a new regulatory benchmark, despite the market’s muted reaction. Additionally, COMPASS Pathways is well-capitalized to continue its operations and invest in medical affairs and commercial planning, which supports the Buy rating and the $45 price target.

In another report released on June 30, Stifel Nicolaus also maintained a Buy rating on the stock with a $11.00 price target.